Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
EDAP TMS ( (EDAP) ) just unveiled an announcement.
On July 1, 2025, EDAP TMS announced its transition from a foreign private issuer to a U.S. domestic filer, effective January 1, 2026. This change signifies a major milestone for the company, highlighting its commitment to transparency and regulatory best practices, and is expected to enhance its relationship with shareholders and attract new institutional investors.
The most recent analyst rating on (EDAP) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on EDAP TMS stock, see the EDAP Stock Forecast page.
Spark’s Take on EDAP Stock
According to Spark, TipRanks’ AI Analyst, EDAP is a Neutral.
EDAP TMS’s overall stock score reflects financial challenges, including negative profitability and cash flow issues, despite promising strategic developments in the HIFU business. Technical analysis and valuation further underscore the caution, as the stock faces bearish sentiment and high risk. The earnings call highlights mixed sentiment, balancing innovation with financial strain.
To see Spark’s full report on EDAP stock, click here.
More about EDAP TMS
EDAP TMS is a recognized leader in robotic energy-based therapies, specializing in the development, manufacturing, promotion, and distribution of minimally invasive medical devices using ultrasound technology. Their flagship product, Focal One®, is a leading prostate focal therapy device used in Europe and the U.S., with potential applications beyond prostate cancer.
Average Trading Volume: 76,227
Technical Sentiment Signal: Sell
Current Market Cap: $62.44M
For an in-depth examination of EDAP stock, go to TipRanks’ Overview page.